You have access
5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.
PANAGIOTIS DIAMANTOPOULOS, KONSTANTINOS ZERVAKIS, VASILIKI PAPADOPOULOU, THEODOROS ILIAKIS, FANI KALALA, NEFELI GIANNAKOPOULOU, NIKI ROUGALA, ATHANASSIOS GALANOPOULOS, PANAGIOTIS BAKARAKOS, ELENI VARIAMI, AGLAIA DIMITRAKOPOULOU and NORA-ATHINA VINIOU
Anticancer Research September 2015, 35 (9) 5141-5147;
